All News about Revance TherapeuticsVia Business Wire
Via Benzinga
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
Via Business Wire
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know
September 09, 2022
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
September 09, 2022
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
September 08, 2022
Via Benzinga
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|